BR112018006537A2 - antagonistas seletivos de nr2b - Google Patents
antagonistas seletivos de nr2bInfo
- Publication number
- BR112018006537A2 BR112018006537A2 BR112018006537A BR112018006537A BR112018006537A2 BR 112018006537 A2 BR112018006537 A2 BR 112018006537A2 BR 112018006537 A BR112018006537 A BR 112018006537A BR 112018006537 A BR112018006537 A BR 112018006537A BR 112018006537 A2 BR112018006537 A2 BR 112018006537A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- nr2b antagonists
- selective nr2b
- selective
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3308DE2015 | 2015-10-14 | ||
| PCT/US2016/056714 WO2017066366A1 (en) | 2015-10-14 | 2016-10-13 | Selective nr2b antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018006537A2 true BR112018006537A2 (pt) | 2018-10-16 |
Family
ID=57223768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018006537A BR112018006537A2 (pt) | 2015-10-14 | 2016-10-13 | antagonistas seletivos de nr2b |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10344020B2 (enExample) |
| EP (1) | EP3362441B1 (enExample) |
| JP (1) | JP6938485B2 (enExample) |
| KR (1) | KR20180063306A (enExample) |
| CN (1) | CN108137543B (enExample) |
| AU (1) | AU2016340237A1 (enExample) |
| BR (1) | BR112018006537A2 (enExample) |
| CA (1) | CA3001890A1 (enExample) |
| EA (1) | EA201890946A1 (enExample) |
| ES (1) | ES2818254T3 (enExample) |
| IL (1) | IL258603A (enExample) |
| MX (1) | MX2018004256A (enExample) |
| WO (1) | WO2017066366A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237103A (zh) * | 2020-12-04 | 2022-10-01 | 瑞士商諾華公司 | 用於治療抑鬱症的ｎｒ２ｂ－ｎｍｄａ受體ｎａｍ之劑量方案 |
| US11646085B2 (en) | 2021-06-17 | 2023-05-09 | Sandisk Technologies Llc | Toggle mode frequency optimization by dynamic ODT matching for non-volatile memory |
| CN116354923B (zh) * | 2021-12-27 | 2025-05-09 | 江苏恩华药业股份有限公司 | 一种含氮杂环化合物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| US7022728B2 (en) * | 2001-03-09 | 2006-04-04 | Abbott Laboratories | Benzimidazoles that are useful in treating male sexual dysfunction |
| MXPA05013151A (es) | 2003-06-04 | 2006-03-17 | Merck & Co Inc | 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b. |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| CN101815518B (zh) | 2007-06-29 | 2013-01-09 | 埃莫里大学 | 用于神经保护的nmda受体拮抗剂 |
| JP2009067784A (ja) * | 2007-08-21 | 2009-04-02 | Shionogi & Co Ltd | 環式基で置換された含窒素複素環誘導体を含有する鎮痛剤 |
| EP2163541A1 (en) | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| US9101612B2 (en) | 2010-02-11 | 2015-08-11 | Northwestern University | Secondary structure stabilized NMDA receptor modulators and uses thereof |
| US9624170B2 (en) * | 2013-12-26 | 2017-04-18 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (MAGL) inhibitors |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| AU2016340239A1 (en) * | 2015-10-14 | 2018-05-31 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
-
2016
- 2016-10-13 BR BR112018006537A patent/BR112018006537A2/pt not_active Application Discontinuation
- 2016-10-13 WO PCT/US2016/056714 patent/WO2017066366A1/en not_active Ceased
- 2016-10-13 CA CA3001890A patent/CA3001890A1/en not_active Abandoned
- 2016-10-13 US US15/767,386 patent/US10344020B2/en active Active
- 2016-10-13 CN CN201680060583.4A patent/CN108137543B/zh active Active
- 2016-10-13 JP JP2018519321A patent/JP6938485B2/ja active Active
- 2016-10-13 EP EP16790475.4A patent/EP3362441B1/en active Active
- 2016-10-13 MX MX2018004256A patent/MX2018004256A/es unknown
- 2016-10-13 KR KR1020187013126A patent/KR20180063306A/ko not_active Abandoned
- 2016-10-13 EA EA201890946A patent/EA201890946A1/ru unknown
- 2016-10-13 ES ES16790475T patent/ES2818254T3/es active Active
- 2016-10-13 AU AU2016340237A patent/AU2016340237A1/en not_active Abandoned
-
2018
- 2018-04-10 IL IL258603A patent/IL258603A/en unknown
-
2019
- 2019-07-03 US US16/502,684 patent/US10961229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200071304A1 (en) | 2020-03-05 |
| US10344020B2 (en) | 2019-07-09 |
| EP3362441B1 (en) | 2020-08-12 |
| IL258603A (en) | 2018-06-28 |
| JP6938485B2 (ja) | 2021-09-22 |
| CN108137543B (zh) | 2021-11-23 |
| MX2018004256A (es) | 2018-05-16 |
| JP2018536637A (ja) | 2018-12-13 |
| US10961229B2 (en) | 2021-03-30 |
| CN108137543A (zh) | 2018-06-08 |
| CA3001890A1 (en) | 2017-04-20 |
| WO2017066366A1 (en) | 2017-04-20 |
| AU2016340237A1 (en) | 2018-05-31 |
| EA201890946A1 (ru) | 2018-09-28 |
| EP3362441A1 (en) | 2018-08-22 |
| KR20180063306A (ko) | 2018-06-11 |
| ES2818254T3 (es) | 2021-04-09 |
| US20180312491A1 (en) | 2018-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000173A (es) | Heteroarilos y usos de estos | |
| MX373307B (es) | Compuestos de biaril-amida como inhibidores de cinasa. | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| EA201691442A1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
| MX380777B (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| MX388170B (es) | Polimorfos de selinexor | |
| UA109792C2 (uk) | Індоли як противірусні агенти відносно респіраторного синтиціального вірусу | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| BR112015022191A8 (pt) | compostos heteroarila e usos dos mesmos | |
| BR112016029612A2 (pt) | compostos de di-hidroisoquinolinona substituídos | |
| MX374452B (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
| MX382607B (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa. | |
| BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| EA201690846A1 (ru) | Замещенные производные пиридина, пригодные в качестве ингибиторов gsk-3 | |
| BR112017004741A2 (pt) | compostos e composições como inibidores da raf quinase | |
| EA201691413A1 (ru) | Селективные антагонисты nr2b | |
| CR20150425A (es) | Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes | |
| EA201690844A1 (ru) | Ингибиторы gsk-3 | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| BR112015029495A2 (pt) | compostos heterocíclicos como inibidores da via de sinalização hedgehog | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| CY1119047T1 (el) | Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| MX372781B (es) | Ciclopentanos 1,2-sustituidos como antagonistas del receptor de la orexina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |